Immunotherapy After Kidney Cancer Surgery
Author Information
Author(s): J Atzpodien, E Schmitt, U Gertenbach, P Fornara, H Heynemann, A Maskow, M Ecke, H H Wöltjen, H Jentsch, W Wieland, T Wandert, M Reitz
Primary Institution: Fachklinik Hornheide an der Universität Münster
Hypothesis
Outpatient immunochemotherapy might extend progression-free and/or overall survival of high-risk renal cell carcinoma patients in the postsurgical adjuvant setting.
Conclusion
Adjuvant immunochemotherapy did not provide a survival benefit compared to observation in high-risk renal cell carcinoma patients after surgery.
Supporting Evidence
- Two-, 5-, and 8-year survival rates were lower in the treatment group compared to the observation group.
- Overall survival was significantly decreased after treatment with immunochemotherapy.
- Relapse-free survival rates did not show significant improvement with treatment.
Takeaway
Doctors tested a new treatment for kidney cancer patients after surgery, but it didn't help them live longer or stay cancer-free compared to just watching and waiting.
Methodology
Patients were randomly assigned to receive either 8 weeks of immunochemotherapy or observation, and their survival rates were compared.
Limitations
The study did not systematically assess toxicity, which could be a concern for patients receiving treatment.
Participant Demographics
Patients aged 18 to 80 years with high-risk renal cell carcinoma post-surgery.
Statistical Information
P-Value
0.0278
Statistical Significance
p=0.0278
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website